Skip to main content

Table 2 Incidence, mortality and utility of long term complications due to high-dose (HD) or standard-dose (SD) chemotherapy for non-seminomatous germ cell cancer.

From: A decision-analytic approach to define poor prognosis patients: a case study for non-seminomatous germ cell cancer patients

Morbidity

References

Incidence

Suspected agent

Mortality

Change in mortality3

Utility4

Change in morbidity5

  

SD

HD

     

Therapy related leukaemia

[10, 22, 23]

0.5%

1.5%

Etoposide (< 2 g/m2, > 2 g/m2)

70%

0.7%

0.90

0.03%

Vascular toxicity

[10, 16, 24, 25]

       

Raynaud's phenomenon

 

25%

>25%

Bleomycin

  

-

-

Cardiovascular disease

 

7%

10%

Cisplatin

10%

0.3%

0.7

0.81%

Neurotoxicity

[5, 10, 21]

       

Peripheral neuropathy

 

4%

5%

Cisplatin

  

-

-

Ototoxicity

 

5%

65%

Cisplatin (<400 mg/m2, > 400 mg/m2)

  

-

-

Nephrotoxicity

[5, 10, 16]

       

Renal failure

 

1%

4%

Cisplatin

  

0.6

1.2%

Hypertension

 

10%

24%

Cisplatin (<400 mg/m2, > 400 mg/m2)

  

0.99

0.14%

Gonadal toxicity

[10, 16, 26, 41]

       

Infertility1

 

50%

>50%

Cisplatin

    

Sexual functioning2

 

15%

27%

   

0.92

0.96%

Total

     

1%

 

3.14%

  1. 1 oligospermia/azoospermia
  2. 2 sexual dissatisfaction
  3. 3 Change in mortality calculated as (incidenceHD-CT - incidenceSD-CT) × fatality
  4. 4 Utility ranges from 0–1 and is a measure of health related quality of life
  5. 5 Change in morbidity calculated as (incidenceHD-CT - incidenceSD-CT) × (1-U) × (1-fatality).